The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

被引：0
|
作者：
Karl-Anton Kreuzer
Richard R. Furman
Stephan Stilgenbauer
Ronald L. Dubowy
Yeonhee Kim
Veerendra Munugalavadla
Esther Lilienweiss
Hans Christian Reinhardt
Paula Cramer
Barbara Eichhorst
Peter Hillmen
Susan M. O’Brien
Andrew R. Pettitt
Michael Hallek
机构：
[1] University of Cologne,Department I of Internal Medicine
[2] Weill Cornell Medical College,Department III of Internal Medicine
[3] Ulm University Medical Center,Center for Molecular Medicine Cologne, and Cologne Excellence Cluster on Cellular Stress Responses in Aging
[4] Gilead Sciences,Associated Diseases (CECAD)
[5] Inc.,undefined
[6] University of Cologne,undefined
[7] St. James’s University Hospital,undefined
[8] University of California-Irvine,undefined
[9] Irvine Chao Family Comprehensive Cancer Center,undefined
[10] University of Liverpool,undefined
来源：
Leukemia | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 300
页数：4
相关论文
共 50 条
  • [21] A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
    O'Brien, Susan M.
    Lamanna, Nicole
    Kipps, Thomas J.
    Flinn, Ian
    Zelenetz, Andrew D.
    Burger, Jan A.
    Keating, Michael
    Mitra, Siddhartha
    Holes, Leanne
    Yu, Albert S.
    Johnson, David M.
    Miller, Langdon L.
    Kim, Yeonhee
    Dansey, Roger D.
    Dubowy, Ronald L.
    Coutre, Steven E.
    BLOOD, 2015, 126 (25) : 2686 - 2694
  • [22] ASCEND Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 21 - 22
  • [23] Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    McKay, John
    Al-Juhaishi, Taha
    Lai Guanhua
    Kmieciak, Maciej
    Sabo, Roy
    Sindel, Ariel
    Yazbeck, Victor
    BLOOD, 2019, 134
  • [24] PHASE 1B STUDY OF IDELALISIB (GS-1101) PLUS CHLORAMBUCIL±RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Barrientos, J.
    Leonard, J.
    Furman, R.
    Flinn, I.
    Vos, S.
    Coutre, S.
    Schreeder, M.
    Wagner-Johnston, N.
    Sharman, J.
    Boyd, T.
    Fowler, N.
    Kimii, Y.
    Holes, L.
    Johnson, D.
    Dansey, R.
    Dubowy, R.
    Rai, K.
    HAEMATOLOGICA, 2013, 98 : 42 - 43
  • [25] Complex karyotype in patients with chronic lymphocytic leukemia.
    Yañez, L
    Cuadrado, MA
    Insunza, A
    Mesones, BG
    Bermudez, A
    Conde, E
    Bureo, E
    Iriondo, A
    BLOOD, 2005, 106 (11) : 328B - 328B
  • [26] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Lilienweiss, Esther
    Bahlo, Jasmin
    Robrecht, Sandra
    Fink, Anna-Maria
    Patz, Michaela
    Tandon, Maneesh
    Jiang, Yanwen
    Schary, William
    Ritgen, Matthias
    Tausch, Eugen
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Fischer, Kirsten
    Hallek, Michael
    Kreuzer, Karl-Anton
    BLOOD, 2020, 135 (11) : 866 - 870
  • [27] Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
    Pagel, John M.
    Coutre, Steven E.
    Furman, Richard R.
    Sharman, Jeff P.
    Cheson, Bruce D.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian W.
    Ghia, Paolo
    Eradat, Herbert A.
    Ervin, Thomas
    Lamanna, Nicole
    Coiffier, Bertrand
    Pettitt, Andrew
    Li, Xiaoming
    Jahn, Thomas M.
    O'Brien, Susan M.
    Hallek, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S201 - S202
  • [28] The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
    Nair, Kruti Sheth
    Cheson, Bruce
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 69 - 84
  • [29] Indirect comparison of ibrutinib versus idelalisib plus ofatumumab in patients with previously treated chronic lymphocytic leukemia
    Sorensen, Sonja
    Tam, Constantine
    Diels, Joris
    Van Sanden, Suzy
    Wildgust, Mark
    Trambitas, Cristina
    Pan, Feng
    Dorman, Emily
    Xu, Yingxin
    Sengupta, Nishan
    LEUKEMIA & LYMPHOMA, 2015, 56 : 155 - 156
  • [30] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
12345